Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
December 2, 2018 Poster

2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

2018 ASH Poster – CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells: View Poster
December 2, 2018 Poster

2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy

2018 ASH Poster – Concomitant Targeting of FLT3 and BTK with CG-806 Overcomes FLT3-Inhibitor Resistance Through Inhibition of Autophagy: View Poster
June 15, 2018 Poster

2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells

2018 EHA Poster - CG-806, a Non Covalent Pan-FLT3/Pan-BTK Inhibitor, Exhibits Unique Binding to Wild Type and C481S Mutant BTK and Greater Potency Than Ibrutinib Against Malignant B Cells: View Poster
April 17, 2018 Poster

APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency

APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency: View Poster
April 15, 2018 Poster

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples: View Poster
April 15, 2018 Poster

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro: View Poster
December 11, 2017 Poster

2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples

2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples: View Poster
December 11, 2017 Poster

2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status

2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status: View Poster
December 10, 2017 Poster

2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1

2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1: View Poster